0001372514-23-000129.txt : 20230921 0001372514-23-000129.hdr.sgml : 20230921 20230921070027 ACCESSION NUMBER: 0001372514-23-000129 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20230920 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230921 DATE AS OF CHANGE: 20230921 FILER: COMPANY DATA: COMPANY CONFORMED NAME: KIORA PHARMACEUTICALS INC CENTRAL INDEX KEY: 0001372514 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36672 FILM NUMBER: 231267715 BUSINESS ADDRESS: STREET 1: 332 ENCINITAS BOULEVARD STREET 2: SUITE 102 CITY: ENCINITAS STATE: CA ZIP: 92024 BUSINESS PHONE: 781-788-8869 MAIL ADDRESS: STREET 1: 332 ENCINITAS BOULEVARD STREET 2: SUITE 102 CITY: ENCINITAS STATE: CA ZIP: 92024 FORMER COMPANY: FORMER CONFORMED NAME: EYEGATE PHARMACEUTICALS INC DATE OF NAME CHANGE: 20060811 8-K 1 kprx-20230920.htm 8-K kprx-20230920
0001372514false00013725142023-09-202023-09-20

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549

FORM 8-K
CURRENT REPORT PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): September 20, 2023
KIORA PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
Delaware
(State or other jurisdiction of incorporation)
001-3667298-0443284
(Commission File Number)(IRS Employer Identification No.)

332 Encinitas Blvd.
Suite 102
Encinitas, CA 92024
(858) 224-9600
(Registrant’s telephone number, including area code)
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class:Trading Symbol(s)Name of each exchange on which registered:
Common Stock, $0.01 par valueKPRXNASDAQ
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o


Item 5.02.    Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On September 20, 2023 (the “Effective Date”), Paul Chaney resigned as Chairman and member of the Board of Directors (the “Board”) of Kiora Pharmaceuticals, Inc. (the “Company”) from the Audit Committee and Nominating and Corporate Governance Committee of the Board, effective as of the Effective Date. Mr. Chaney did not resign as a result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.

In connection with Mr. Chaney’s retirement from the Board, as of the Effective Date, the Board appointed Praveen Tyle, Ph.D. as Chairman of the Board. Additionally, the Board appointed Erin Parsons as Chair of the Compensation Committee of the Board, and appointed Carmine Stengone as a member of the Audit Committee and the Nominating and Corporate Governance Committee of the Board, in each case effective as of the Effective Date.

Item 7.01.    Regulation FD Disclosure.
On September 21, 2023, the Company issued a press release announcing the appointment of Dr. Tyle as Chairman, a copy of which is attached as Exhibit 99.1 to this Current Report and is incorporated herein by reference.

Information contained on or accessible through any website reference in the press releases is not part of, or incorporated by reference in, this Current Report, and the inclusion of such website addresses in this Current Report by incorporation by reference of the press releases is an inactive textual references only.
Item 9.01.    Financial Statements and Exhibits.
(d) Exhibits.
Exhibit 
Number		Title
104Cover Page Interactive Data File (embedded within the Inline XBRL document).


SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
KIORA PHARMACEUTICALS, INC.
By:/s/ Melissa Tosca
Melissa Tosca
Executive Vice President of Finance
(Principal financial and accounting officer)
Date: September 21, 2023

 EX-99.1 2 ex991-pressreleaseseptembe.htm EX-99.1 Document

Exhibit 99.1

Kiora Pharmaceuticals Appoints Praveen Tyle, PhD, as New Chairman; Succeeds Paul Chaney Who is Retiring After Serving 17 Years

September 21, 2023 -- Encinitas, CA -- Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) announced that its board of directors has appointed Praveen Tyle, PhD, who currently serves as a director, as its new Chairman. Dr. Tyle succeeds current Chairman Paul Chaney who is retiring after serving 17 years on the board.

“We look forward to Dr. Tyle’s leadership as Chairman, where he’ll continue to bring valuable industry experience in guiding our development of new treatments for eye disease,” said Brian M. Strem, PhD, President and CEO of Kiora. “We want to thank Paul for his dedication to the Company over the years, his mentorship to the team, and his support for our sharpened focus on retinal disease."

Dr. Tyle is an accomplished executive in the pharmaceutical industry with a track record of leadership in innovation and business growth. He will continue to help guide Kiora's strategic direction as the Company advances the development of KIO-301, its molecular photoswitch, through clinical development for retinitis pigmentosa, choroideremia, and other inherited retinal diseases.

"I welcome the opportunity to serve as the Chairman and look forward to working with Brian and the rest of the board,” said Dr. Tyle. “The board would also like to extend its appreciation to Paul for his service to the Company. We strongly believe in the strategic direction that Brian and the leadership team have conceived and are now implementing."

About Kiora Pharmaceuticals
Kiora Pharmaceuticals is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. KIO-301 is being developed for the treatment of Retinitis Pigmentosa, and Kiora also plans to develop KIO-301 for Choroideremia and Stargardt's Disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. Kiora plans to develop KIO-104 for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory and small molecule inhibitor of Dihydroorotate Dehydrogenase (DHODH) with what Kiora believes is best-in-class picomolar potency and a validated immune modulating mechanism (blocks T cell proliferation and proinflammatory cytokine release). In addition to news releases and SEC filings, we expect to post information on our website, www.kiorapharma.com, and social media accounts that could be relevant to investors. We encourage investors to follow us on Twitter and LinkedIn as well as to visit our website and/or subscribe to email alerts.

Forward-Looking Statements
Some of the statements in this press release are "forward-looking" and are made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995. These "forward-looking" statements include statements relating to, among other things, the development and commercialization efforts and other regulatory or marketing approval efforts pertaining to Kiora's development-stage products, including KIO-301 and KIO-104, as well as the success thereof, with such approvals or success may not be obtained or achieved on a timely basis or at all, and Kiora's ability to reach a quorum at the adjourned Special Meeting. These statements involve risks and uncertainties that may cause results to differ materially from the statements set forth in this press release, including, among other things, the ability to conduct clinical trials on a timely basis, the ability to obtain any required regulatory approvals, market and other conditions and certain risk factors described under the heading "Risk Factors" contained in Kiora's Annual Report on Form 10-K filed with the SEC on March 23, 2023, or described in Kiora's other public filings. Kiora's results may also be affected by factors of which Kiora is not currently aware. The forward-looking statements in this press release speak only as of the date of this press release. Kiora expressly disclaims any obligation or undertaking to release publicly any updates or revisions to such statements to reflect any change in its expectations with regard thereto or any changes in the events, conditions, or circumstances on which any such statement is based, except as required by law.

Contact
investors@kiorapharma.com


 EX-101.SCH 3 kprx-20230920.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 kprx-20230920_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Entity Central Index Key Entity Central Index Key Entity Address, Address Line Two Entity Address, Address Line Two Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Trading Symbol Trading Symbol Entity File Number Entity File Number Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Soliciting Material Soliciting Material Entity Address, City or Town Entity Address, City or Town Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Local Phone Number Local Phone Number Entity Address, Postal Zip Code Entity Address, Postal Zip Code Written Communications Written Communications City Area Code City Area Code Cover [Abstract] Title of 12(b) Security Title of 12(b) Security Document Type Document Type Amendment Flag Amendment Flag Security Exchange Name Security Exchange Name Entity Registrant Name Entity Registrant Name Entity Emerging Growth Company Entity Emerging Growth Company Entity Address, State or Province Entity Address, State or Province Document Period End Date Document Period End Date Pre-commencement Tender Offer Pre-commencement Tender Offer EX-101.PRE 5 kprx-20230920_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 6 R1.htm IDEA: XBRL DOCUMENT v3.23.3
Cover
Sep. 20, 2023
Cover [Abstract]  
Document Type 8-K
Document Period End Date Sep. 20, 2023
Entity Registrant Name KIORA PHARMACEUTICALS, INC.
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 98-0443284
Entity File Number 001-36672
Entity Address, Address Line One 332 Encinitas Blvd.
Entity Address, Address Line Two Suite 102
Entity Address, City or Town Encinitas
Entity Address, State or Province CA
Entity Address, Postal Zip Code 92024
City Area Code 858
Local Phone Number 224-9600
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, $0.01 par value
Trading Symbol KPRX
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Entity Central Index Key 0001372514
Amendment Flag false
XML 7 kprx-20230920_htm.xml IDEA: XBRL DOCUMENT 0001372514 2023-09-20 2023-09-20 0001372514 false 8-K 2023-09-20 KIORA PHARMACEUTICALS, INC. DE 001-36672 98-0443284 332 Encinitas Blvd. Suite 102 Encinitas CA 92024 858 224-9600 false false false false Common Stock, $0.01 par value KPRX NASDAQ false EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.3 html 1 23 1 false 0 0 false 0 false false R1.htm 0000001 - Document - Cover Sheet http://www.eyegatepharma.com/role/Cover Cover Cover 1 false false All Reports Book All Reports kprx-20230920.htm kprx-20230920.xsd kprx-20230920_lab.xml kprx-20230920_pre.xml http://xbrl.sec.gov/dei/2022 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "kprx-20230920.htm": { "nsprefix": "kprx", "nsuri": "http://www.eyegatepharma.com/20230920", "dts": { "inline": { "local": [ "kprx-20230920.htm" ] }, "schema": { "local": [ "kprx-20230920.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] }, "labelLink": { "local": [ "kprx-20230920_lab.xml" ] }, "presentationLink": { "local": [ "kprx-20230920_pre.xml" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2022": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 24, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2022": 23 }, "report": { "R1": { "role": "http://www.eyegatepharma.com/role/Cover", "longName": "0000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "kprx-20230920.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "kprx-20230920.htm", "first": true, "unique": true } } }, "tag": { "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "Security12bTitle", "presentation": [ "http://www.eyegatepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.eyegatepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.eyegatepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.eyegatepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "DocumentType", "presentation": [ "http://www.eyegatepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.eyegatepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "SolicitingMaterial", "presentation": [ "http://www.eyegatepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Soliciting Material", "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.eyegatepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "CityAreaCode", "presentation": [ "http://www.eyegatepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.eyegatepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.eyegatepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "PreCommencementTenderOffer", "presentation": [ "http://www.eyegatepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Pre-commencement Tender Offer", "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "LocalPhoneNumber", "presentation": [ "http://www.eyegatepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://www.eyegatepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Pre-commencement Issuer Tender Offer", "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "AmendmentFlag", "presentation": [ "http://www.eyegatepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "SecurityExchangeName", "presentation": [ "http://www.eyegatepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityRegistrantName", "presentation": [ "http://www.eyegatepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.eyegatepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityFileNumber", "presentation": [ "http://www.eyegatepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.eyegatepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "WrittenCommunications", "presentation": [ "http://www.eyegatepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Written Communications", "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "TradingSymbol", "presentation": [ "http://www.eyegatepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityAddressAddressLine2", "presentation": [ "http://www.eyegatepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line Two", "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 14 0001372514-23-000129-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001372514-23-000129-xbrl.zip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